RxDoctor Payments Data

Gregg Zimmerman, MD

Urology · Denville, NJNPI 1790766228

Payments from drug & device makers

$9,024in general payments, 2019–2025

Across 374 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Johnson & Johnson$843
  • Pfizer$667
  • Astellas Pharma US Inc$533
  • Myriad Genetic Laboratories, Inc.$481
  • Bayer$430
  • plus $5K from 48 others

What the payments were for

  • Travel & lodging$3214%
  • Food & beverage$8,37593%
  • Education$2933%
  • Gifts$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,024 in reported general payments places this provider in the 75th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$492,330
Medicare patients
1,087
Services billed
11,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron125$134,621
MyrbetriqMirabegron85$84,785
Tamsulosin Hcl507$9,753
Silodosin48$3,380
Finasteride174$2,602
Testosterone34$2,243
Potassium Citrate ErPotassium Citrate17$2,043
Dutasteride50$1,235
Tadalafil16$1,129
Alfuzosin Hcl ErAlfuzosin Hcl47$1,026
Solifenacin Succinate12$493
Oxybutynin Chloride ErOxybutynin Chloride22$436
CefuroximeCefuroxime Axetil64$277
Sildenafil Citrate26$259
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen50$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$339$134,621125 claims
Astellas Pharma US IncMyrbetriq$533$84,78585 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 401 urology providers in New Jersey.

Other urology in Denville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →